Meeting
2013 ASCO Annual Meeting
Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses.
Authors
Jason T. Huse
Memorial Sloan-Kettering Cancer Center, New York, NY
Jason T. Huse , Kathryn Beal , Jianan Zhang , Edward R. Kastenhuber , Thomas Joseph Kaley , Lauren E. Abrey , Philip H. Gutin , Cameron W Brennan , Antonio Marcilio Padula Omuro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01392209
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2057)
DOI
10.1200/jco.2013.31.15_suppl.2057
Abstract #
2057
Poster Bd #
3E
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman
Poster
2017 ASCO Annual Meeting
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Phioanh Leia Nghiemphu